Caribou Biosciences Ownership
| CRBU Stock | USD 1.20 0.04 3.23% |
Caribou |
Caribou Stock Ownership Analysis
About 63.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.4. Some equities with similar Price to Book (P/B) outperform the market in the long run. Caribou Biosciences has Price/Earnings To Growth (PEG) ratio of 0.5. The entity recorded a loss per share of 1.66. The firm had not issued any dividends in recent years. Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. The company was incorporated in 2011 and is headquartered in Berkeley, California. Caribou Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on Caribou Biosciences please contact Rachel Haurwitz at 510 982 6030 or go to https://cariboubio.com.Besides selling stocks to institutional investors, Caribou Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Caribou Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Caribou Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Caribou Biosciences Quarterly Liabilities And Stockholders Equity |
|
About 10.0% of Caribou Biosciences are currently held by insiders. Unlike Caribou Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Caribou Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Caribou Biosciences' insider trades
Caribou Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Caribou Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Caribou Biosciences backward and forwards among themselves. Caribou Biosciences' institutional investor refers to the entity that pools money to purchase Caribou Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fmr Inc | 2024-12-31 | 1.6 M | Two Sigma Advisers, Llc | 2024-12-31 | 1.5 M | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 1.2 M | Two Sigma Investments Llc | 2024-12-31 | 1.1 M | Goldman Sachs Group Inc | 2024-12-31 | 1.1 M | Point72 Asset Management, L.p. | 2024-12-31 | 1 M | Jpmorgan Chase & Co | 2024-09-30 | 866.7 K | Fidelity International Ltd | 2024-09-30 | 860.7 K | Millennium Management Llc | 2024-12-31 | 859.8 K | Blackrock Inc | 2024-12-31 | 6.6 M | Vanguard Group Inc | 2024-12-31 | 4.6 M |
Caribou Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Caribou Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Caribou Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Caribou Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Caribou Biosciences Outstanding Bonds
Caribou Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Caribou Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Caribou bonds can be classified according to their maturity, which is the date when Caribou Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Caribou Stock Analysis
When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.